Antioxidants as potential therapeutics for neuropsychiatric disorders
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abdalla, 1986, Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients, Clin Chem, 32, 805, 10.1093/clinchem/32.5.805
Adler, 1993, Vitamin E treatment of tardive dyskinesia, Am J Psychiatry, 150, 1405, 10.1176/ajp.150.9.1405
Akanji, 2007, Associations of blood homocysteine concentrations in Arab schizophrenic patients, Clin Biochem, 40, 1026, 10.1016/j.clinbiochem.2007.06.001
Akyol, 2002, The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance, Prog Neuropsychopharmacol Biol Psychiatry, 26, 995, 10.1016/S0278-5846(02)00220-8
Altuntas, 2000, Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients, Clin Chem Lab Med, 38, 1277, 10.1515/CCLM.2000.201
Amminger, 2010, Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial, Arch Gen Psychiatry, 67, 146, 10.1001/archgenpsychiatry.2009.192
Andreazza, 2007, Serum S100B and antioxidant enzymes in bipolar patients, J Psychiatr Res, 41, 523, 10.1016/j.jpsychires.2006.07.013
Andreazza, 2008, Oxidative stress markers in bipolar disorder: a meta-analysis, J Affect Disord, 111, 135, 10.1016/j.jad.2008.04.013
Andreazza, 2009, 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder, J Psychiatry Neurosci, 34, 263
Arvindakshan, 2003, Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients, Biol Psychiatry, 53, 56, 10.1016/S0006-3223(02)01443-9
Atmaca, 2005, The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia, Psychiatry Clin Neurosci, 59, 652, 10.1111/j.1440-1819.2005.01432.x
Babior, 1978, Oxygen-dependent microbial killing by phagocytes, N Engl J Med, 298, 659, 10.1056/NEJM197803232981205
Balanza-Martinez, 2011, Therapeutic use of omega-3 fatty acids in bipolar disorder, Expert Rev Neurother, 11, 1029, 10.1586/ern.11.42
Ben Othmen, 2008, Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings, Prog Neuropsychopharmacol Biol Psychiatry, 32, 155, 10.1016/j.pnpbp.2007.08.003
Ben-Shachar, 2004, Mitochondria, synaptic plasticity, and schizophrenia, Int Rev Neurobiol, 59, 273, 10.1016/S0074-7742(04)59011-6
Berger, 2007, Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial, J Clin Psychiatry, 68, 1867, 10.4088/JCP.v68n1206
Berk, 2008, N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial, Biol Psychiatry, 64, 361, 10.1016/j.biopsych.2008.03.004
Berk, 2011, The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial, J Affect Disord, 135, 389, 10.1016/j.jad.2011.06.005
Bilici, 2001, Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments, J Affect Disord, 64, 43, 10.1016/S0165-0327(00)00199-3
Boskovic, 2011, Oxidative stress in schizophrenia, Curr Neuropharmacol, 9, 301, 10.2174/157015911795596595
Brown, 1998, Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia, Biol Psychiatry, 43, 863, 10.1016/S0006-3223(97)00197-2
Bulut, 2009, Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia, World J Biol Psychiatry, 10, 626, 10.1080/15622970903144004
Burton, 2010, Oxidative stress, Best Pract Res Clin Obstet Gynaecol, 25, 287, 10.1016/j.bpobgyn.2010.10.016
Calder, 2011, Fatty acids and inflammation: the cutting edge between food and pharma, Eur J Pharmacol, 668, S50, 10.1016/j.ejphar.2011.05.085
Carlsson, 1999, Neurotransmitter interactions in schizophrenia—therapeutic implications, Biol Psychiatry, 46, 1388, 10.1016/S0006-3223(99)00117-1
Carmeli, 2012, Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial, PLoS One, 7, e29341, 10.1371/journal.pone.0029341
Casademont, 2007, Euroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients, J Clin Psychopharmacol, 27, 284, 10.1097/JCP.0b013e318054753e
Chen, 2003, Neurotrophic and neurotoxic effects of zinc on neonatal cortical neurons, Neurochem Int, 42, 471, 10.1016/S0197-0186(02)00154-7
Chengappa, 2000, Inositol as an add-on treatment for bipolar depression, Bipolar Disord, 2, 47, 10.1034/j.1399-5618.2000.020107.x
Cichy, 2009, Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors, Pharmacol Rep, 61, 1184, 10.1016/S1734-1140(09)70182-3
Clayton, 2009, Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation, Eur J Clin Nutr, 63, 1037, 10.1038/ejcn.2008.81
Corrigan, 1993, Vitamin E treatment of tardive dyskinesia, Am J Psychiatry, 150, 991, 10.1176/ajp.150.6.991c
Dabiri, 1994, Effectiveness of vitamin E for treatment of long-term tardive dyskinesia, Am J Psychiatry, 151, 925, 10.1176/ajp.151.6.925
Dakhale, 2005, Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia, Psychopharmacology (Berl), 182, 494, 10.1007/s00213-005-0117-1
Dietrich-Muszalska, 2005, Oxidative stress in blood platelets from schizophrenic patients, Platelets, 16, 386, 10.1080/09537100500128872
Dietrich-Muszalska, 2009, Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia, Neuropsychobiology, 59, 1, 10.1159/000202822
Do, 2000, Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo, Eur J Neurosci, 12, 3721, 10.1046/j.1460-9568.2000.00229.x
Do, 2009, Redox dysregulation, neurodevelopment, and schizophrenia, Curr Opin Neurobiol, 19, 220, 10.1016/j.conb.2009.05.001
Dodd, 2008, N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility, Expert Opin Biol Ther, 8, 1955, 10.1517/14728220802517901
Dragsted, 2008, Biomarkers of exposure to vitamins A, C, and E and their relation to lipid and protein oxidation markers, Eur J Nutr, 47, 3, 10.1007/s00394-008-2003-1
Eden Evins, 2006, Inositol augmentation of lithium or valproate for bipolar depression, Bipolar Disord, 8, 168, 10.1111/j.1399-5618.2006.00303.x
Emsley, 2002, Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia, Am J Psychiatry, 159, 1596, 10.1176/appi.ajp.159.9.1596
Evans, 2003, Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment, Prostaglandins Leukot Essent Fatty Acids, 69, 393, 10.1016/j.plefa.2003.08.010
Fenton, 2000, Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia, Biol Psychiatry, 47, 8, 10.1016/S0006-3223(99)00092-X
Fenton, 2001, A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am J Psychiatry, 158, 2071, 10.1176/appi.ajp.158.12.2071
Ferret, 2000, Protective effect of thioredoxin upon NO-mediated cell injury in THP1 monocytic human cells, Biochem J, 346, 759, 10.1042/0264-6021:3460759
Franco, 2008, Involvement of glutathione, ERK1/2 phosphorylation and BDNF expression in the antidepressant-like effect of zinc in rats, Behav Brain Res, 188, 316, 10.1016/j.bbr.2007.11.012
Frangou, 2006, Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study, Br J Psychiatry, 188, 46, 10.1192/bjp.188.1.46
Frederickson, 2000, Importance of zinc in the central nervous system: the zinc-containing neuron, J Nutr, 130, 1471S, 10.1093/jn/130.5.1471S
Freeman, 2008, Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study, J Affect Disord, 110, 142, 10.1016/j.jad.2007.12.228
Fusar-Poli, 2012, Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies, J Clin Psychopharmacol, 32, 179, 10.1097/JCP.0b013e318248b7bb
Galecki, 2009, Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients, Hum Psychopharmacol, 24, 277, 10.1002/hup.1014
Gawryluk, 2011, Decreased levels of lutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders, Int J Neuropsychopharmacol, 14, 123, 10.1017/S1461145710000805
Gergerlioglu, 2007, Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment, Prog Neuropsychopharmacol Biol Psychiatry, 31, 697, 10.1016/j.pnpbp.2006.12.020
Ghosh, 1997, NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid, Mol Cell Biochem, 166, 35, 10.1023/A:1006841228483
Goff, 1995, Tardive dyskinesia and substrates of energy metabolism in CSF, Am J Psychiatry, 152, 1730, 10.1176/ajp.152.12.1730
Golse, 1977, Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses, Nouv Presse Med, 6, 2449
Hanzawa, 2011, No association between glutathione-synthesis-related genes and Japanese schizophrenia, Psychiatry Clin Neurosci, 65, 39, 10.1111/j.1440-1819.2010.02157.x
Harman, 1993, Free radical involvement in aging. Pathophysiology and therapeutic implications, Drugs Aging, 3, 60, 10.2165/00002512-199303010-00006
Harper, 2011, Maternal serum docosahexaenoic acid and schizophrenia spectrum disorders in adult offspring, Schizophr Res, 128, 30, 10.1016/j.schres.2011.01.009
Hedelin, 2010, Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population, BMC Psychiatry, 10, 38, 10.1186/1471-244X-10-38
Herken, 2001, Red blood cell nitric oxide levels in patients with schizophrenia, Schizophr Res, 52, 289, 10.1016/S0920-9964(00)00169-9
Hogg, 1997, S-Nitrosoglutathione as a substrate for gamma-glutamyl transpeptidase, Biochem J, 323, 477, 10.1042/bj3230477
Horrobin, 1994, The membrane hypothesis of schizophrenia, Schizophr Res, 13, 195, 10.1016/0920-9964(94)90043-4
Hughes, 1999, Relationships between nitric oxide, nitroxyl ion, nitrosonium cation and peroxynitrite, Biochim Biophys Acta, 1411, 263, 10.1016/S0005-2728(99)00019-5
Ito, 2005, Antioxidant action of eugenol compounds: role of metal ion in the inhibition of lipid peroxidation, Food Chem Toxicol, 43, 461, 10.1016/j.fct.2004.11.019
Jakob, 1986, Prenatal developmental disturbances in the limbic allocortex in schizophrenics, J Neural Transm, 65, 303, 10.1007/BF01249090
Johnson, 1996, Reactive oxygen species are downstream mediators of p53-dependent apoptosis, Proc Natl Acad Sci U S A, 93, 11848, 10.1073/pnas.93.21.11848
Keck, 2006, Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder, Biol Psychiatry, 60, 1020, 10.1016/j.biopsych.2006.03.056
Kendler, 2003, The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries, Am J Psychiatry, 160, 1549, 10.1176/appi.ajp.160.9.1549
Khan, 1997, Oxidative stress and superoxide dismutase in schizophrenia, Biochem Soc Trans, 25, 418S, 10.1042/bst025418s
Khan, 2002, Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics, Schizophr Res, 58, 1, 10.1016/S0920-9964(01)00334-6
Khanzode, 2003, Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors, Redox Rep, 8, 365, 10.1179/135100003225003393
Kodydkova, 2009, Antioxidative enzymes and increased oxidative stress in depressive women, Clin Biochem, 42, 1368, 10.1016/j.clinbiochem.2009.06.006
Kornhuber, 1994, Current status of biochemical hypotheses in the pathogenesis of schizophrenia, Nervenarzt, 65, 741
Kotan, 2011, Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study, Prog Neuropsychopharmacol Biol Psychiatry, 35, 1284, 10.1016/j.pnpbp.2011.03.021
Kuloglu, 2002, Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder, Cell Biochem Funct, 20, 171, 10.1002/cbf.940
Kupfer, 2005, The increasing medical burden in bipolar disorder, JAMA, 293, 2528, 10.1001/jama.293.20.2528
Lai, 2012, The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials, J Affect Disord, 136, e31, 10.1016/j.jad.2011.06.022
Li, 2006, Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study, J Zhejiang Univ Sci B, 7, 981, 10.1631/jzus.2006.B0981
Li, 2011, Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 35, 1064, 10.1016/j.pnpbp.2011.03.001
Lohr, 1990, Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia, Biol Psychiatry, 28, 535, 10.1016/0006-3223(90)90490-S
Loven, 1996, Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients, Biol Psychiatry, 40, 230, 10.1016/0006-3223(95)00669-9
Machado-Vieira, 2007, Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects, Neurosci Lett, 421, 33, 10.1016/j.neulet.2007.05.016
Maes, 2010, Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression, Neuro Endocrinol Lett, 32, 133
Maes, 2011, A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness, Prog Neuropsychopharmacol Biol Psychiatry, 35, 676, 10.1016/j.pnpbp.2010.05.004
Maes, 2012, New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors, Inflammopharmacology, 20, 127, 10.1007/s10787-011-0111-7
Magalhães, 2011, N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial, J Affect Disord, 129, 317, 10.1016/j.jad.2010.08.001
Magalhaes, 2011, N-acetylcysteine for major depressive episodes in bipolar disorder, Rev Bras Psiquiatr, 33, 374, 10.1590/S1516-44462011000400011
Mahadik, 2001, Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 25, 463, 10.1016/S0278-5846(00)00181-0
Marazziti, 2012, Psychiatric disorders and mitochondrial dysfunctions, Eur Rev Med Pharmacol Sci, 16, 270
Matsuzawa, 2008, Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study, PLoS One, 3, e1944, 10.1371/journal.pone.0001944
McCreadie, 1995, The Nithsdale Schizophrenia Surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects, Br J Psychiatry, 167, 610, 10.1192/bjp.167.5.610
McLoughlin, 1990, Zinc in depressive disorder, Acta Psychiatr Scand, 82, 451, 10.1111/j.1600-0447.1990.tb03077.x
McNamara, 2011, Long-chain omega-3 fatty acid deficiency in mood disorders: rationale for treatment and prevention, Curr Drug Discov Technol
Merikangas, 2007, The impact of comorbidity of mental and physical conditions on role disability in the US adult household population, Arch Gen Psychiatry, 64, 1180, 10.1001/archpsyc.64.10.1180
Michel, 2004, Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis, J Neural Transm, 111, 1191, 10.1007/s00702-004-0160-9
Mico, 2011, Reduced antioxidant defense in early onset first-episode psychosis: a case–control study, BMC Psychiatry, 11, 26, 10.1186/1471-244X-11-26
Mischoulon, 2009, A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder, J Clin Psychiatry, 70, 1636, 10.4088/JCP.08m04603
Mocchegiani, 2005, Brain, aging and neurodegeneration: role of zinc ion availability, Prog Neurobiol, 75, 367, 10.1016/j.pneurobio.2005.04.005
Mukerjee, 1996, Impaired antioxidant defense at the onset of psychosis, Schizophr Res, 19, 19, 10.1016/0920-9964(95)00048-8
Mukherjee, 1996, Diabetes mellitus in schizophrenic patients, Compr Psychiatry, 37, 68, 10.1016/S0010-440X(96)90054-1
Nemets, 2002, Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder, Am J Psychiatry, 159, 477, 10.1176/appi.ajp.159.3.477
Nemets, 2006, Omega-3 treatment of childhood depression: a controlled, double-blind pilot study, Am J Psychiatry, 163, 1098, 10.1176/ajp.2006.163.6.1098
Nowak, 1999, Alterations in serum and brain trace element levels after antidepressant treatment: part I, Zinc. Biol Trace Elem Res, 67, 85, 10.1007/BF02784278
Nowak, 2004, Zinc treatment induces cortical brain-derived neurotrophic factor gene expression, Eur J Pharmacol, 492, 57, 10.1016/j.ejphar.2004.03.038
Osher, 2005, Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study, J Clin Psychiatry, 66, 726, 10.4088/JCP.v66n0608
Ozcan, 2004, Antioxidant enzyme activities and oxidative stress in affective disorders, Int Clin Psychopharmacol, 19, 89, 10.1097/00004850-200403000-00006
Pearce, 2001, Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms, Mol Psychiatry, 6, 634, 10.1038/sj.mp.4000956
Peet, 2002, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J Psychiatr Res, 36, 7, 10.1016/S0022-3956(01)00048-6
Peet, 1993, Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment, Int Clin Psychopharmacol, 8, 151, 10.1097/00004850-199300830-00003
Pillai, 2008, Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia, Neurosignals, 16, 183, 10.1159/000111562
Raffa, 2011, Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients, BMC Psychiatry, 11, 124, 10.1186/1471-244X-11-124
Raffa, 2012, Reduced antioxidant defense systems in schizophrenia and bipolar I disorder, Prog Neuropsychopharmacol Biol Psychiatry, 39, 371, 10.1016/j.pnpbp.2012.07.013
Ranjekar, 2003, Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients, Psychiatry Res, 121, 109, 10.1016/S0165-1781(03)00220-8
Reddy, 1991, Enzymes of the antioxidant defense system in chronic schizophrenic patients, Biol Psychiatry, 30, 409, 10.1016/0006-3223(91)90298-Z
Rezin, 2009, Mitochondrial dysfunction and psychiatric disorders, Neurochem Res, 34, 1021, 10.1007/s11064-008-9865-8
Richard, 2008, Polyunsaturated fatty acids as antioxidants, Pharmacol Res, 57, 451, 10.1016/j.phrs.2008.05.002
Rossi, 1980, Biochemical aspects of phagocytosis in polymorphonuclear leucocytes. NADH and NADPH oxidation by the granules of resting and phagocytizing cells, Experientia, 20, 21, 10.1007/BF02146019
Sarandol, 2007, Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative–antioxidative systems, Hum Psychopharmacol, 22, 67, 10.1002/hup.829
Sarris, 2011, Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials, Bipolar Disord, 13, 454, 10.1111/j.1399-5618.2011.00945.x
Sarris, 2012, Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression, J Clin Psychiatry, 73, 81, 10.4088/JCP.10r06710
Savas, 2006, Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes, World J Biol Psychiatry, 7, 51, 10.1080/15622970510029993
Selek, 2008, The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode, J Affect Disord, 107, 89, 10.1016/j.jad.2007.08.006
Shriqui, 1992, Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study, Am J Psychiatry, 149, 391, 10.1176/ajp.149.3.391
Singh, 2010, Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia, Int J Neuropsychopharmacol, 13, 257, 10.1017/S1461145709990654
Slater, 1995, Signalling mechanisms and oxidative stress in apoptosis, Toxicol Lett, 82–83, 149, 10.1016/0378-4274(95)03474-9
Sowa-Kucma, 2008, Antidepressant-like activity of zinc: further behavioral and molecular evidence, J Neural Transm, 115, 1621, 10.1007/s00702-008-0115-7
Srivastava, 2001, Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients, Psychopharmacology (Berl), 158, 140, 10.1007/s002130100860
Srivastava, 2002, A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression, J Affect Disord, 72, 45, 10.1016/S0165-0327(01)00421-9
Stoklasova, 1986, Glutathione peroxidase activity in the blood in chronic schizophrenia, Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl, 29, 103
Stoll, 1999, Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial, Arch Gen Psychiatry, 56, 407, 10.1001/archpsyc.56.5.407
Su, 2008, Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 69, 644, 10.4088/JCP.v69n0418
Sublette, 2011, Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression, J Clin Psychiatry, 72, 1577, 10.4088/JCP.10m06634
Suboticanec, 1990, Vitamin C status in chronic schizophrenia, Biol Psychiatry, 28, 959, 10.1016/0006-3223(90)90061-6
Szewczyk, 2011, The role of zinc in neurodegenerative inflammatory pathways in depression, Prog Neuropsychopharmacol Biol Psychiatry, 35, 693, 10.1016/j.pnpbp.2010.02.010
Takeda, 2009, Insight into zinc signaling from dietary zinc deficiency, Brain Res Rev, 62, 33, 10.1016/j.brainresrev.2009.09.003
Thome, 1998, Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article, J Neural Transm, 105, 85, 10.1007/s007020050040
Traber, 2011, Vitamins C and E: beneficial effects from a mechanistic perspective, Free Radic Biol Med, 51, 1000, 10.1016/j.freeradbiomed.2011.05.017
Virit, 2009, A defect in the antioxidant defense system in schizophrenia, Neuropsychobiology, 60, 87, 10.1159/000239684
Whatley, 1998, Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients, Mol Psychiatry, 3, 227, 10.1038/sj.mp.4000375
Yanik, 2003, Is the arginine–nitric oxide pathway involved in the pathogenesis of schizophrenia?, Neuropsychobiology, 47, 61, 10.1159/000070010
Yao, 2011, Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view, Antioxid Redox Signal, 15, 2011, 10.1089/ars.2010.3603
Yao, 1998, Effects of haloperidol on antioxidant defense system enzymes in schizophrenia, J Psychiatr Res, 32, 385, 10.1016/S0022-3956(98)00028-4
Yao, 1998, Reduced level of plasma antioxidant uric acid in schizophrenia, Psychiatry Res, 80, 29, 10.1016/S0165-1781(98)00051-1
Yao, 1999, Human plasma glutathione peroxidase and symptom severity in schizophrenia, Biol Psychiatry, 45, 1512, 10.1016/S0006-3223(98)00184-X
Yao, 2000, Abnormal age-related changes of plasma antioxidant proteins in schizophrenia, Psychiatry Res, 97, 137, 10.1016/S0165-1781(00)00230-4
Yao, 2006, Altered glutathione redox state in schizophrenia, Dis Markers, 22, 83, 10.1155/2006/248387
Yilmaz, 2007, Increased levels of nitric oxide, cortisol and drenomedullin in patients with chronic schizophrenia, Med Princ Pract, 16, 137, 10.1159/000098367
Zhang, 1998, Progress in the study of mammalian selenoprotein, Sheng Li Ke Xue Jin Zhan, 29, 29
Zhang, 2006, The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial, Psychopharmacology (Berl), 188, 12, 10.1007/s00213-006-0476-2
Zhang, 2007, Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia, J Clin Psychiatry, 68, 754, 10.4088/JCP.v68n0513